Angiotech’s licensee, Cook Medical, announces single-arm study reveals 86.2 percent SFA vessel patency for Zilver(R …

Angiotech’s licensee, Cook Medical, announces single-arm study reveals 86.2 percent SFA vessel patency for Zilver(R …
VANCOUVER, May 25 /PRNewswire-FirstCall/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced Cook Medical, a license holder of Angiotech’s paclitaxel technology, presented one-year data at Euro PCR that confirms sustained clinical outcomes with Cook Medical’s drug-eluting peripheral stent, Zilver(R) PTX(TM). According to data presented today by Prof. Dierk Scheinert …

Read more on SYS-CON Media

More Meth Drug Addiction Info:

• Espresso Guide: Crema Patency (w/ double ristretto)
• Angiotech's licensee, Cook Medical, announces single-arm study …
• First Personal Injury Calls for More GP Checks – PR Newswire …
• Apical transportation created using three different patency …
• Failure to achieve clinical improvement despite graft patency in …
• Patency and durability of presewn multiple branched graft for …
• Five Clinical Presentations Highlight Shionogi Pharma, Inc.'s …
• Sanofi-aventis Establishes Strategic Alliance with MIT's Center …
• Gentium Reports First Quarter Financial Results | The Chronicus Post
• PROLOR Biotech Announces New Listing on Tel Aviv Stock Exchange …